Capstone Asset Management’s Idexx Laboratories IDXX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2017
Q2
$2.77M Sell
17,178
-500
-3% -$81.2K 0.08% 307
2017
Q1
$2.73M Buy
17,678
+7,006
+66% +$966K 0.08% 311
2016
Q4
$1.25M Buy
10,672
+1,690
+19% +$193K 0.04% 525
2016
Q3
$1.01M Sell
8,982
-370
-4% -$39K 0.03% 586
2016
Q2
$868K Buy
9,352
+710
+8% +$61K 0.03% 628
2016
Q1
$677K Buy
8,642
+220
+3% +$15.8K 0.02% 738
2015
Q4
$614K Sell
8,422
-1,474
-15% -$105K 0.02% 792
2015
Q3
$735K Buy
9,896
+740
+8% +$53K 0.02% 681
2015
Q2
$587K Sell
9,156
-1,004
-10% -$69.5K 0.02% 857
2015
Q1
$785K Sell
10,160
-398
-4% -$31K 0.02% 796
2014
Q4
$783K Buy
10,558
+60
+0.6% +$4.21K 0.02% 762
2014
Q3
$618K Buy
10,498
+460
+5% +$29.1K 0.02% 863
2014
Q2
$670K Sell
10,038
-570
-5% -$36.2K 0.02% 851
2014
Q1
$644K Buy
10,608
+200
+2% +$11.9K 0.02% 869
2013
Q4
$554K Sell
10,408
-5,442
-34% -$286K 0.02% 1041
2013
Q3
$790K Buy
15,850
+1,360
+9% +$65.4K 0.02% 935
2013
Q2
$650K Buy
+14,490
New +$633K 0.02% 1007

Other funds holding IDXX

Capstone Asset Management's IDXX Position: Q2 2017 in Review

Capstone Asset Management reduced its Idexx Laboratories (IDXX) stake by 2.8% in Q2 2017, selling an estimated $81.2K and leaving 17,178 shares worth $2.77M. The position accounts for 0.08% of the portfolio, ranked #307.

Capstone Asset Management first reported a position in IDXX in Q2 2013 and has held it in 17 quarters since. 582 funds tracked by Wall St. Rank hold IDXX as of Q2 2017.

  • Capstone Asset Management held 17,178 shares of Idexx Laboratories worth $2.77M as of Q2 2017.
  • Capstone Asset Management sold 500 Idexx Laboratories shares in Q2 2017, an estimated $81.2K.
  • Idexx Laboratories made up 0.08% of Capstone Asset Management's portfolio in Q2 2017, its #307 holding.
  • Capstone Asset Management first reported a position in Idexx Laboratories in Q2 2013 and has held it in 17 quarters since.
  • 582 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2017.

Based on Capstone Asset Management's 13F filing for Q2 2017, filed 10 Jul 2017.